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Glucose uptakeInsulin signaling to the glomerular podocyte is important for normal kidney function and is implicated in the
pathogenesis of diabetic nephropathy (DN). This study determined the role of the insulin receptor substrate 2
(IRS2) in this system. Conditionally immortalized murine podocytes were generated from wild-type (WT) and
insulin receptor substrate 2-deﬁcient mice (Irs2−/−). Insulin signaling, glucose transport, cellular motility and
cytoskeleton rearrangement were then analyzed. Within the glomerulus IRS2 is enriched in the podocyte and
is preferentially phosphorylated by insulin in comparison to IRS1. Irs2−/− podocytes are signiﬁcantly insulin
resistant in respect to AKT signaling, insulin-stimulated GLUT4-mediated glucose uptake, ﬁlamentous
actin (F-actin) cytoskeleton remodeling and cell motility. Mechanistically, we discovered that Irs2 deﬁciency
causes insulin resistance through up-regulation of the phosphatase and tensin homolog (PTEN). Importantly,
suppressing PTEN in Irs2−/− podocytes rescued insulin sensitivity. In conclusion, this study has identiﬁed for
the ﬁrst time IRS2 as a critical molecule for sensitizing the podocyte to insulin actions through its ability to
modulate PTEN expression. This ﬁnding reveals two potential molecular targets in the podocyte for modulating
insulin sensitivity and treating DN.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Diabetic nephropathy (DN) is amajor complication of diabetes, with
up to 40% of patients experiencing this problem [1]. It is the leading
cause of end-stage renal failure in the world [2]. The natural history of
DN is dominated by progressive albuminuria [3], making the glomerular
podocyte an attractive early target cell. Podocytes are highly specialized,
terminally differentiated, cells that are critically important for pre-
venting albumin to escape into the urine. Indeed there are now in excess
of 35podocyte speciﬁc humanmutations, all ofwhich result in albumin-
uria [4]. Albuminuria is detrimental as it is a prelude to end-stage renalceptor; PTEN, phosphatase and
n's RenalUnit, School of Clinical
dom.
stigaciones Biomédicas Alberto
oward), avalverde@iib.uam.esfailure in diabetic and non-diabetic diseases [2]. It is also independently
linked to cardiovascular morbidity and mortality [3]. Podocytes are im-
portant early target cells in the pathogenesis of DN as evidenced by
podocyte number and morphology being excellent predictors of DN
progression [5–10]. Previous studies by our group [11,12] and others
[13,14] have shown that podocytes are insulin responsive cells, and
that they signal through the phosphoinositide 3-kinase (PI3K) and
mitogen-activated protein kinase (MAPK) pathways to induce a variety
of biological effects.Moreover, a loss of podocyte insulin sensitivity in
the intact perfused glomerulus results in an albuminuric phenotype
with features reminiscent of DN but in a normoglycaemic environment
[12,15]. Recently, it has been shown that insulin signaling is also impor-
tant in modulating other cellular processes in the podocyte including
endoplasmic reticulum stress [14] and mitochondrial function [16].
Therefore, understanding the key signaling pathways and proteins
that control insulin actions in this cell type is highly desirable.
A critical node in the insulin signaling pathway is the insulin recep-
tor substrate (IRS) family of proteins. The IRS family contains at least
four members, including IRS1, IRS2, IRS3, and IRS4. IRS1 and IRS2 are
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dominantly expressed in mouse adipose tissue and IRS4 is expressed in
the pituitary, thymus and brain [17]. IRS1 and IRS2 are docking proteins
that transduce signaling cascades emerging from the IR that regulate a
variety of processes including metabolism, cellular growth, develop-
ment and survival [18]. Although IRS1 and IRS2 share similar protein
structure and expression patterns, several lines of evidence suggest a
tissue-speciﬁcity of IRS-mediated signaling in growth and metabolism
[19–21]. Mice with whole body deletion of IRS1 (Irs1−/−) display re-
duced body size, insulin resistance and β-cell hyperplasia [19]. In con-
trast, whole body IRS2-deﬁcient mice (Irs2−/−) have defects in
hepatic insulin action [20–22] and β-cell insufﬁciency leading to hyper-
glycemia due to impaired insulin-like growth factor-1 (IGF-1) receptor
mitogenic signaling [20]. Consequently, male Irs2−/− mice develop
type-2-like diabetes andmost die around 16weeks of age due to diabet-
ic complications. Conversely, IRS3 and IRS4 are not essential for normal
growth, glucose homeostasis or glucose transport, as illustrated by
whole body murine knockout models [17].
This study shows that within the glomerulus IRS2 is enriched in the
podocyte and that its deletion causes a loss of biochemical and func-
tional metabolic insulin signaling in these cells. Furthermore, IRS2 loss
in the podocyte up-regulates the phosphatase and tensin homolog
(PTEN) which inhibits PI3K signaling. Importantly, insulin signaling
can be rescued in IRS2-deﬁcient podocytes by suppressing PTEN
expression.
2. Materials and methods
Additional methods are included in the supplementary material.
2.1. Generation of immortalized podocyte cell lines
Conditionally immortalized murine podocytes were generated from
wild-type (mPodWT) and Irs2−/− (mPodIRS2KO) mice on a mixed
C57BL6 x 129Sv genetic background at 12 weeks of age following the
protocol previously described [23]. Different clones of each cell line
were studied to avoid possible clonal effects
2.2. Cellular stimulation
To assess insulin signaling, differentiated mPodWT and mPodIRS2KO
were starved of fetal bovine serum (FBS) and insulin for at least 8 h prior
to stimulation. Cells were then treated with insulin or IGF-1 at doses
ranging from 1 to 100 nM for 15 min. When insulin doses are not speci-
ﬁed, 100 nM was used. To assess post-puromycin stress, differentiated
mPodWT and mPodIRS2KO were deprived of FBS for at least 8 h prior
to stimulation with puromycin aminucleoside (50 μg/ml), a podocyte
toxin for 18 h
2.3. Measurement of 2-deoxyglucose uptake
For the analysis of insulin-induced 2-deoxyglucose (2-DOG) uptake,
we followed the protocol previously described [12]. Brieﬂy, podocytes
were grown to conﬂuence and each experiment was performed with
equal matched samples of basal and insulin-stimulated wells. After 12
h of FBS and insulin starvation, cells were stimulated for 15 min with
insulin and matched control wells treated with PBS (vehicle). [3H] 2-
deoxyglucose (DOG) was added to the basal and insulin-stimulated
cells at a concentration of 50 μM (1 μCi/ml) for the last 5 min of the
incubation
2.4. Subcellular fractionation
Cells were homogeneized in lysis buffer as previously described [24].
After sequential centrifugations, the Triton X-100-soluble component
(plasma membrane fraction) was separated from the Triton-insolublematerial (cytoskeletal fraction) by high-speed centrifugation and was
analyzed by Western blot.
2.5. Immunoprecipitation and Western blot
Total protein extracts were separated by SDS-PAGE under reducing
conditions. Membranes were incubated with the following primary an-
tibodies: anti-GLUT4 (Santa Cruz), anti-PTP1B, anti-IRS1, anti-IRS2,
anti-phosphotyrosine (4G10) (Merk-Millipore), anti-phospho-AKT
(Thr308), anti-IR, anti-PTEN, anti-phospho-AKT (Ser473), anti-
phospho-p44/42-MAPK (Thr202/Tyr204), anti-AKT (pan), anti-p44/
42-MAPK (Cell Signalling). Anti-SV40-LTAg and anti-nephrin antibodies
were a gift from K. Trygvasson (Stockholm, Sweden). Blots were then
probed with mouse monoclonal anti-α tubulin or anti-β actin anti-
bodies (Sigma) as protein loading controls. For immunoprecipitation,
equals amounts of protein were immunoprecipitated with the corre-
sponding antibodies. The immune complexeswere collected on agarose
beads and submitted to Western blot analysis.
2.6. Cell viability assay
Cell viability was quantiﬁed by the CellTiter 96® AQueous One Solu-
tion Cell Proliferation Assay (Promega,Madison,WI, USA) following the
manufacturer's instructions.
2.7. Scratch assay
Cells were seeded to conﬂuence. The scratch was performed using a
pipette tip and then, the media was changed. Images of the regions of
interest were taken at time 0 and after 18 h. The percentage of cells in
the area of the denuded clear zone was measured using the Image J
software.
2.8. Immunoﬂuorescence
Cells were seeded on glass coverslip slides (Menzel-Gläser,
Braunschweig, Germany) and stained with polyclonal anti-GLUT4 anti-
body (Santa Cruz Biotechnology, Palo Alto, CA). The F-actin cytoskele-
ton was visualized using phalloidin-conjugated FITC (Invitrogen,
Carlsbad, CA). Immunoﬂuorescence was examined in a Nikon Eclipse
90imicroscopewith imaging softwareNis elements (Nikon) or in a con-
focal microscope LSM710 (Zeiss) with Zen 2011 software (Leica).
2.9. Transduction of Irs2–deﬁcient podocytes by adenoviral infection
DifferentiatedmPodIRS2KOwere infectedwith 10MOI (multiplicity
of infection or viral particles per cell) of IRS2 or mock (β-galactosidase)
adenoviruses. Podocytes were routinely infected for 36 h as previously
described [25], after which mPodIRS2KO recovered IRS2 expression.
Then, cells were used for further experiments.
2.10. Transient transfection with siRNA
mPodIRS2KO were transfected with 25 nM PTEN siRNA or with a
scrambled control siRNA following DharmaFECT General Transfection
Protocol. After 48 h, cells were used for experiments. Transfection efﬁ-
ciency was evaluated by real-time qPCR and Western blot.
2.11. RNA extraction and quantitative real-time polymerase chain reaction
(qPCR)
Total RNAwas extracted from podocytes using TRI Reagent (Sigma).
1 μg of RNA was reverse transcribed with High Capacity cDNA Archive
Kit (Applied Biosystems, Foster City, CA, USA). Real-time qPCRwas per-
formedwith anABI 7900 sequence detector using the SyBr Greenmeth-
od and d(N)6 random hexamer with the primers for mouse PTEN [26].
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TTGTACACA3´ and Rv 5´ GCCTCACTAAACCATCCAATCG3´).2.12. Short hairpin PTP1B knockdown
Speciﬁc shRNA mouse protein tyrosine phosphatase 1B (PTP1B) or
control (scrambled) lentiviral transduction particles (Sigma) were
used to produce stable knockdown murine podocyte cell lines. These
clones were then selected, expanded and examined for their levels of
PTP1B. Transfection efﬁciency was evaluated by real-time qPCR and
Western blot.Fig. 1. IRS2 is expressed in podocytes and is phosphorylated in response to insulin. A)Western
human glomerular endothelial cell line (GEnC). Loading control ofβ-actin is shown. B) Condition
doses for 15min. Total protein was immunoprecipitatedwith anti-IRS2 antibodies and analyzed
phosphorylation. D) Murine podocytes were stimulated with insulin or IGF-1 for 15 min. Total
with anti-pTYR or anti-IRS1 antibodies. E) Quantiﬁcation of IRS1 tyrosine phosphorylation. Resu
vs Basal and in E) *pb 0.05 IGF-1(100 ng/ml) vs.Basal F)Western blot analysis of total protein ex
nephrin and SV40-LTAg are shown.G) Total protein extracts frommPodWT andmPodIRS2KOp
insulin signaling cascade using α-tubulin as a loading control. Results are representative of 3 in2.13. In vivo studies
Wild-type (Irs2+/+) and IRS2-deﬁcient (Irs2−/−) mice were
maintained on a similar mixed genetic background (C57BL/6 x
129Sv) as previously described [27]. Anesthesia and perioperative
analgesia were used to maintain animal well-being throughout the
experiments. Three weeks after the onset of hyperglycemia, urine
was collected. All animal husbandry was carried out in accordance
with in accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki). Experimental procedures
were performed with the appropriate governmental and institutional
ethical and legal approval.blot analysis of IRS2 in a human podocyte cell line (hPod), total glomeruli (Gloms) and in a
ally immortalizedmurinepodocyteswere stimulatedwith insulin or IGF-1 at the indicated
byWestern blot with anti-pTYR or anti-IRS2 antibodies. C) Quantiﬁcation of IRS2 tyrosine
protein was immunoprecipitated with anti-IRS1 antibodies and analyzed byWestern blot
lts are expressed in fold-change overmPodWT controls and aremean± SD. In C) *p b 0.01
tracts ofmPodWT andmPodIRS2KOpodocytes at 33 °C and 37 °C. Representative images of
odocytes at 33 °C and 37 °Cwere loaded. RepresentativeWestern blot of key proteins of the
dependent experiments.
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Urine was collected for 24 h in mouse metabolism cages
(Technoplast®). Urinary albumin and creatinine levels were measured
using Urinary Albuwell® and Creatinine Companion® kits (Exocell,
PA, USA). Blood was collected via cardiac puncture and plasma creati-
nine levels were measured by HPLC. Creatinine clearance as a measure
of estimated glomerular ﬁltration rate (eGFR) was calculated using the
following formula: Urine vol (μl) x urine creatinine (mg/dl)/plasma
creatinine (mg/dl) × 1440 (min). Results were corrected to total body
weight prior sacriﬁce to provide eGFR.
2.15. Transmission electron microscopy
Electron microscopy was performed as previously described [28]
with slight modiﬁcations. Blinded analysis of glomerular histology was
performed by an experienced histopathologist.
2.16. Statistical analysis
Results are expressed as mean ± SD of at least three indepen-
dent experiments. Statistical analysis was performed using SPSS
(SPSS Inc., Chicago, IL) software. When comparing two groups
non-parametric (Mann–Whitney-Wilcoxon and Kruskal-Wallis)
analysis was used. When analyzing multiple groups one- ANOVA
analysis was performed with bonferroni post hoc and Tukey Kramer
multiple comparison test. A p value less than 0.05 were deemed
signiﬁcant.
3. Results
3.1. IRS2 is enriched in the podocyte within the glomerulus and
phosphorylated by insulin
Immortalized human glomerular cell lines demonstrated that IRS2
expression was enriched in the podocyte, with minimal signal detected
in either glomerular endothelial cells (GEnC) or whole glomerular
lysates (Fig. 1A). Furthermore, wild-type murine podocytes also
showed a robust expression of IRS2. Immunoprecipitation studies re-
vealed that insulin rapidly phosphorylated IRS2 in comparison to
IRS1 at doses ranging from 10 to 100 nM (Fig. 1B,C). In contrast, IGF-1
stimulation preferentially phosphorylated IRS1 in comparison to IRS2
(Fig. 1D,E).
To further explore the role of IRS2 in the podocyte, conditionally
immortalized temperature-sensitive large T antigen Irs2−/− (mPodIRS2KO)
and wild-type (mPodWT) podocyte cell lines were generated from
12-week-old mice. Immortalized podocytes were studied in their dif-
ferentiated state after 14 days of thermo-switching to 37 °C in which
they expressed the podocyte-speciﬁc protein nephrin and also the
key components of the insulin signaling cascade including IRS1, AKT
and p44/42-MAPK similar to the mPodWT controls (Fig. 1F,G). The
absence of IRS2 was conﬁrmed in the mPodIRS2KO by genotyping
and analyzing protein levels (Supplementary Fig. 1A,1B, Fig. 1G). Im-
portantly, the expression of p27 was up-regulated in both types of
podocytes after thermo-switching, illustrating cell cycle arrest and
terminal differentiation (Supplementary Fig. 1C).
3.2. IRS2 is essential for insulin signaling and insulin actions in podocytes
In response to insulin stimulation, podocytes are able to rapidly
absorb glucose via the glucose transporters GLUT4 and GLUT1, and
this process is dependent on the ﬁlamentous actin (F-actin) cytoskele-
ton [12] and nephrin [11]. Since IRS proteins act as central integrators
of insulin signaling [29], we analyzed the impact of Irs2 deletion on
these parameters. Irs2 deﬁciency in podocytes (mPodIRS2KO) resulted
in a signiﬁcant reduction of basal glucose uptake and also in thecomplete abrogation of insulin-stimulated glucose uptake (Fig. 2A).
Irs2 loss also reduced insulin-stimulated translocation of GLUT4 from
cytosol to the plasma membrane. Additionally, basal level of GLUT4 at
the plasma membrane was decreased in mPodIRS2KO consistent with
the decreased basal glucose uptake (Fig. 2B, C, D).
Irs2 deletion also impaired F-actin dynamics and motility in
podocytes with a marked reduction of insulin-stimulated cortical
F-actin remodeling (Fig. 3A,B) and a reduction of podocyte cell motility
measured with scratch assays (Fig. 3C,D).
3.3. IRS2 modulates AKT-signaling in podocytes
To elucidate the mechanism by which the absence of IRS2 induced
insulin resistance in podocytes, we interrogated the insulin-signaling
pathway in these cells. Insulin-stimulated insulin receptor (IR) tyrosine
phosphorylation was preserved in mPodIRS2KO (Fig. 4A, Supplemen-
tary Fig. 2A), as was IRS1 expression and its tyrosine phosphorylation
(Fig. 4B, Supplementary Fig. 2B). However, AKT phosphorylation was
signiﬁcantly impaired at both Ser 473 and Thr 308 residues (Fig. 4C,D)
when IRS2 was absent. Notably, basal AKT Thr 308 phosphorylation
was increased in mPodIRS2KO, but did not further increase in response
to insulin stimulation. Insulin stimulated p44/42-MAPK phosphoryla-
tion was similar between the two cell types although again, basal phos-
phorylation levels were higher in mPodIRS2KO. Although we found
differences in AKT signaling in mPodIRS2KO and this is critical for insu-
lin action in podocytes [30], we didn't detect differences in the survival
properties of mPodIRS2KO in comparison to wild-type podocytes when
stressed with puromycin (Fig. 4E).
3.4. Knockdown of PTEN, but not PTP1B, rescues insulin sensitivity in
Irs2-deﬁcient podocytes
We then examined whether we could manipulate the insulin-
signaling pathway in Irs2-deﬁcient podocytes to rescue insulin sensi-
tivity. We targeted two well-known negative cellular regulators of
insulin signaling; protein tyrosine phosphatase 1B (PTP1B) which
has been shown to inhibit insulin signaling at the level of IR and is
expressed in podocytes [31], and PTEN that regulates AKT activity
in the PI3K pathway [32]. No differences were found in PTP1B
mRNA (data not shown) or protein expression levels between
mPodIRS2KO and mPodWT podocytes (Fig. 5A, B). Furthermore,
shRNA-mediated stable PTP1B knockdown in mPodIRS2KO cells
that reduced PTP1B mRNA levels by 95% did not rescue insulin-
stimulated AKT phosphorylation (Fig. 5C, Supplementary Fig. 2C). In-
terestingly, we found that the loss of IRS2 caused a prolonged over-
expression of PTEN (Fig. 5D, E), and that short-term genetic reconsti-
tution of IRS2 by adenoviral transfer did not restore the insulin re-
sponse in AKT phosphorylation at Ser 473 or reduce PTEN over-
expression (Fig. 5F, G, Supplementary Fig. 2D). However, when
PTEN was knocked down using siRNA technology (Fig. 6A, B) it re-
sulted in the rescue of insulin-induced AKT phosphorylation, glucose
uptake, GLUT4 translocation (Fig. 6B, C, E) and F-actin remodeling
(Fig. 6D, F).
3.5. Irs2-deﬁcient mice develop early features of diabetic nephropathy
Whole body Irs2-deﬁcient mice were assessed for glomerular pa-
thology. We found that male Irs2−/− mice were markedly diabetic
and developed signiﬁcant albuminuria by 12-weeks of age with a
loss of podocyte foot process architecture in comparison to their
wild-type (Irs2+/+) littermate controls (Table 1, Fig. 7, Supplemen-
tary Fig. 3A, B). Unfortunately, it was difﬁcult to assess the speciﬁc
contribution of IRS2 loss to podocyte dysfunction in this setting
due to the severity of diabetes. Indeed, age and strain-matched
mice rendered equally diabetic by STZ injections also developed
Fig. 2. Immortalizedpodocytes from Irs2-deﬁcientmice are insulin resistant in respect to glucoseuptake andGLUT4 translocation. A) 2-DOGuptakewasmeasured following stimulation of
podocytes with or without insulin. Results are mean ± SD of 4 independent experiments and are expressed as fold-change of basal mPodWT. *p b 0.05 and **p b 0.005. B) Immuno-
ﬂuorescence of GLUT4 in mPodWT and mPodIRS2KO podocytes upon insulin stimulation. GLUT4 located at the plasma membrane is indicated by arrows (scale bar 10 μm). Note in the
magniﬁed sections, that GLUT 4 is unable to translocate to the plasma membrane upon insulin stimulation in mPodIRS2KO. Representative images of 5 independent experiments are
shown. C) Representative Western blot detecting GLUT4 in plasma membrane extracts using caveolin 1 as a plasmamembrane loading control. D) Quantiﬁcation of GLUT4 translocation
to the plasma membrane analyzed by Western blot. Results are mean ± SD of 4 independent experiments. *p b 0.05 vs. basal mPodWT.
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Fig. 3C, D).
4. Discussion
This work demonstrates that IRS2 is a critical molecule in the insulin
signaling pathway in the podocyte. IRS2 loss here results in a severe
insulin resistance that is coordinated through the negative regulator of
insulin signaling, PTEN.
IRS2 is widely expressed in insulin sensitive tissues and in the brain.
Insulin and IGF-1 signaling through IRS2 coordinates life span exten-
sion, metabolic regulation and cognition [33]. In the kidney, it hasbeen shown that IRS2 is expressed in the tubules and increases in diabe-
tes [34]. We now demonstrate that within the glomerulus IRS2 is also
enriched in the podocyte compartmentwhich constitutes approximate-
ly 10% of total glomerular cells [35].
IRS2 is a key mediator of insulin signaling in podocytes downstream
of the IR, as demonstrated by the diminished response of Irs2-deﬁcient
podocytes to insulin in respect of glucose uptake, GLUT4 translocation,
F-actin cytoskeleton organization and cell motility. At the molecular
level, Irs2 deﬁciency here resulted in an impaired insulin-mediated
AKT phosphorylation despite intact IR and IRS1 tyrosine phosphoryla-
tion responses. These results are consistent with previous data from
our laboratory demonstrating the inability of IRS1 to activate PI3K in
Fig. 3. Irs2-deﬁcient podocytes have impaired insulin-mediated F-actin cytoskeleton rearrangement and motility. A) F-actin cytoskeleton was analyzed by immunoﬂuorescence with
phalloidin staining. Insulin-stimulated mPodWT cells show cortically reorganized F-actin (arrow), but cortical reorganization was not observed in mPodIRS2KO cells (scale
bars 5000 μm). Representative images are shown. B) Quantiﬁcation of cell number with F-actin cortical reorganization using Image J software. Results are mean ± SD of 4 independent
experiments.**p b 0.001 vs. other groups. C) Representative images of the wound healing at 18 h after scratching. Originalmagniﬁcation 100×D) Quantiﬁcation of the percentage of cells
in the scratched area. Results are mean ± SD of 5 independent experiments. **p b 0.001 vs. mPodWT.
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27,36], and also with data in podocytes from db/db mice that show a
blockade in insulin-induced AKT phosphorylation despite preserved
IRS1 levels [13]. This is relevant as both IRS1 and IRS2 can efﬁciently ac-
tivate the PI3K and MAPK pathways in other insulin sensitive tissues
[33] and highlights the cellular speciﬁcity of IRS2 as a critical node of
the insulin signaling pathway in podocytes. Conversely, elsewhere in
the glomerular ﬁltration barrier, in glomerular endothelial cells, IRS1
has been shown to be an essential mediator of insulin signaling, indicat-
ing a high degree of cellular speciﬁcity of IRS protein functions within
glomeruli [37]. Based on that, our data suggest distinct functions of
IRS1 and IRS2 in the podocyte in regard to insulin signaling (through
IRS2) and IGF-1 signaling (through the IGF-1R). It is also interesting
that there was no obvious compensation for IRS2 and insulin sensitivityloss through IRS1. Therefore, speciﬁc effects of insulin [15] and IGF-1
[38] in podocytes might be the result of the differential activation of
IRS2 or IRS1, respectively. Elucidating the cellular signaling pathways
for these two hormonal axeswill allow speciﬁc targeting andmanipula-
tion of the insulin and IGF systems.
The involvement of IRS proteins in insulin-mediated AKT signaling,
GLUT4 translocation or glucose uptake differs depending on the cellular
context. In L6 myotubes, IRS1 activation increases insulin-induced
glucose uptake, GLUT4 translocation and actin remodeling whereas
Irs2 deletion does not affect these responses [39]. However, in brown
adipocytes, insulin-mediated glucose transport and GLUT4 transloca-
tion are through IRS2, suggesting that podocytes and adipocytes display
similar requirements of IRS2 in respect to insulin stimulated activation
of AKT, GLUT4 translocation and glucose uptake [40]. Interestingly, it
Fig. 4. Impaired AKT signaling in Irs2-deﬁcient podocytes. Podocytes were serum-starved and stimulated with insulin. Total protein was immunoprecipitated with A) anti-IR or B) anti-
IRS1 antibodies and analyzed by Western blot with anti-pTYR and anti–IR or anti-IRS1 antibodies. Results are representative of 3 independent experiments C) Representative Western
blots using the indicated antibodies. D)Quantiﬁcation ofWestern blot analysis. Results aremean±SD of 5 independent experiments. *pb 0.05 vs. basalmPodWT. E) Podocyte cell viability
post-puromycin stress. mPodIRS2KO andmPodWTwere serum-starved and stimulatedwith puromycin. Results aremean± SD of 5 independent experiments. *p b 0.05 vs. their respec-
tive controls.
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GLUT4 in podocytes thatmodulate their size and number [41], although
it is unknown if these effects are modiﬁed by the IRS family. It is also
clear that AKT2 has an important role in podocytes viability [30].
However, we didn't detect differences in the susceptibility to cell
death of mPodIRS2KO indicating the existence of additional mecha-
nisms independent of IRS2 that modulate podocytes viability.
After discovering that the loss of IRS2 rendered the podocytes insulin
resistant, we explored the mechanism underlying this effect and
attempted to reverse it. We focused on PTP1B [42] and PTEN [43], two
relevant molecules characterized as negative modulators of insulin sig-
naling. Our previous data have demonstrated that the suppression of
PTP1B in the liver of Irs2−/−mice can restore insulin signaling through
an IRS1-mediated PI3K/AKT signaling pathway [27]. This was not the
case in the podocyte. This, again, demonstrates the cellular speciﬁcity
of insulin signaling pathways in different tissues, but is not entirelysurprising as the negative effects on insulin actions of PTP1B are pre-
dominantly mediated through the IR and IRS proteins [42], which are
proximally located in the insulin signaling cascade. We then targeted
PTEN, a lipid phosphatase that dephosphorylates PtdIns-3,4,5-P3
in vivo and is a negative modulator of insulin signaling downstream of
the IR/IRS complex [44–46]. Recently, it has been shown that the im-
pairment of insulin induction of glucose uptake into podocytes cultured
in the presence of high glucose concentrations for long time-periods is
associated with increased PTEN levels [32]. We found that Irs2 deﬁcien-
cy increased PTEN levels which elicited a negative regulation of AKT by
dephosphorylating the Ser 473 residue as described [47]. Moreover, this
constitutive PTEN elevation might further impact the function of
other phosphatases since we found up-regulated basal Akt Thr 308
phosphorylation. This effect seems to be the consequence of the cellular
adaptation to prolonged Irs2 deﬁciency, since acute (36 h) IRS2 recon-
stitution into podocytes failed to restore PTEN back to normal levels
Fig. 5.Differential expression of negativemodulators (PTP1B and PTEN) of insulin signaling in podocytes fromwild-type and Irs2-deﬁcientmice. A)RepresentativeWestern blotwith anti-
PTP1B antibody B) Quantiﬁcation of PTP1B protein expression. Results are mean ± SD of 4 independent experiments. C) Podocyte cell lines (mPodWT, mPodIRS2KO, mPodIRS2KO/
PTP1BKO) were serum-starved and stimulated with insulin. Western blot analysis of IRS2, PTP1B, pAKT (Ser 473) and α-tubulin as a loading control. Similar results were obtained in 3
independent experiments. D) Western blot analysis of PTEN in non-stimulated podocytes. E) Quantiﬁcation of PTEN protein expression in non-stimulated podocytes. Results
are mean ± SD of 4 independent experiments. *p b 0.05 vs. mPodWT. F) mPodIRS2KO were infected with adenoviruses encoding IRS2 (Ad IRS2) or GFP as a mock control.
After 36 h, cells were serum-starved and stimulated with insulin. Western blot analysis with the indicated antibodies. Five different experiments were performed with similar
results. G) Western blot analysis with anti-PTEN antibody using α tubulin as a loading control. Similar results were obtained in 3 independent experiments.
3231B. Santamaria et al. / Biochimica et Biophysica Acta 1853 (2015) 3224–3234and did not reverse insulin resistance. Encouragingly, PTEN silencing
rescued insulin-induced AKT signaling in Irs2-deﬁcient podocytes and,
as a consequence, also rescued insulin-induced GLUT4 translocation,
glucose uptake and F-actin cytoskeleton reorganization. These results
suggest that PTEN constitutes a key point of regulation of insulin signal-
ing in Irs2-deﬁcient insulin resistant podocytes. Our ﬁndings are in
agreement with data of Kushner and co-workers that found increased
AKT and Foxo1 phosphorylation in the islets of Irs2−/−/Pten+/− mice
[48].
A reciprocal interaction between IRS2 and PTEN has been described
in tumor cell lines. In MDA-MB-468 breast cancer cells, reduced PtdIns-
3,4,5-P3 levels elicited a feedback mechanism involving IRS2 up-
regulation that attempted to restore PtdIns-3,4,5-P3 content in order
to circumvent apoptosis and growth inhibition [49,50]. Conversely,PTEN knock-down in mouse embryonic ﬁbroblasts decreased IRS2 ex-
pression [49,50]. We show an inverse reciprocal modulation in which
Irs2 deletion increases PTEN, thereby blocking AKT phosphorylation
downstream of IRS proteins. Thus, targeting PTEN in Irs2-deﬁcient
podocytes can sensitize this cell to insulin which may be beneﬁcial
in preventing kidney disease, particularly in DN. A recent study in
podocytes found that PTEN inhibition altered cytoskeletal dynamics,
resulting in changes in the permeability and barrier function [51]. Dif-
ferences in the podocyte origin could account for such differences. It
should also be remembered that PTEN is a tumor suppressor and
great care should be taken in therapeutically targeting PTEN in insulin
resistance, especially if it has systemic effects on other cell types.
Finally, we extended our study to examine the glomerular effects of
IRS2 in whole body Irs2-deﬁcient mice. These mice developed severe
Fig. 6. PTEN silencing rescues insulin-mediated AKT phosphorylation, glucose uptake, GLUT4 translocation to the plasma membrane and F-actin cytoskeleton rearrangement in
Irs2-deﬁcient podocytes. mPodIRS2KO podocytes were transfected with control (scrambled-SCR) or PTEN siRNAs for 48 h followed by stimulation with insulin. A) Pten mRNA
quantiﬁcation using 18S as a housekeeping gene. Results are mean± SD of 4 independent experiments. *p b 0.05 vs. SCR. B) Protein extracts were analyzed byWestern blot with
the indicated antibodies. Three independent experiments were performed with similar results. C) 2-DOG uptake was measured following stimulation with or without insulin.
Results are expressed as fold-change versus mPodIRS2KO podocytes transfected with control scrambled siRNA. Results are mean ± SD of 4 independent experiments. *p b 0.05 vs.
mPodIRS2KO siPTEN. D) Quantiﬁcation of number of cells with F-actin cortical reorganization using Image J software. Results are mean ± SD of 4 independent experiments. *p b 0.01
vs. other groups. E) GLUT4 translocation to the plasma membrane was analyzed by immunoﬂuorescence. Localization of GLUT4 at plasma membrane is indicated by an arrow (scale
bars 100 μm). A magniﬁcation area indicates GLUT4 translocation to the membrane. Representative images are shown. F) F-actin cytoskeleton reorganization was analyzed with
phalloidin staining (scale bars 10,000 μm). Insulin-stimulated F-actin reorganization is indicated by an arrow. Representative images are shown.
3232 B. Santamaria et al. / Biochimica et Biophysica Acta 1853 (2015) 3224–3234diabetes and kidney disease, but we are unable to decipher if this was
partially or completely due to the loss of IRS2 in the podocyte or to
the systemic effects of diabetes. Going forward it will be interesting to
speciﬁcally delete IRS2 from the podocyte to explore this issue more
fully in non-diabetic and diabetic environments. Based on these and
previous ﬁndings, we conclude that IRS2 has differential functions in
different parts of the kidney. In the tubules it modulates renal ﬁbrosis
during DN [34,52], and in the podocyte it is important for insulinsensitivity, glucose uptake and cytoskeleton function. Similarly, differ-
ing roles of mTORC1 between the glomeruli and tubules in DN have
also been reported [53,54].
5. Conclusion
As summarized in Fig. 8, thiswork reveals that IRS2 is a keymolecule
in insulin signaling in the podocyte since its deﬁciency causes insulin
Fig. 7. Diabetic Irs2−/− mice have podocyte foot process effacement. A) Representative
TEM images of kidneys from wild-type and Irs2−/−mice. Four mice per group were ana-
lyzed. Foot process widening in kidneys from Irs2−/−mice is shown (white arrows).
Table 1
Renal clinical-pathological correlates in male wild-type (Irs2+/+) and Irs2−/−mice.
Mean Age 5–6 weeks 13–14 weeks
Genotype Irs2+/+ Irs2−/− Irs2+/+ Irs2−/−
Fasting Blood Glucose (mmol/l) 7.25 ± 0.23 (8) 12.6 ± 1.06 (8)*** 7.36 ± 0.389 (10) 25.16 ± 3.39 (6)***
Urine volume (ml/day) 0.70 ± 0.13 (8) 0.95 ± 0.21 (6) 0.54 ± 0.09 (10) 33.94 ± 4.93 (6)***
UAE (μg/day) 11.23 ± 2.08 (8) 7.52 ± 1.87 (6) 8.60 ± 2.25 (10) 77.48 ± 24.11 (6)***
UACR (μg/mg) 29.16 ± 3.18 (8) 33.10 ± 6.08 (6) 27.53 ± 4.42 (10) 72.37 ± 16.46 (7)**
Serum creatinine (μmol/l) 8.84 ± 1.76 (5) 9.72 ± 0.88 (5) 12.38 ± 0.88 (9) 11.49 ± 0.88 (7)
Creatinine clearance (μl/min/g body weight) 12.40 ± 1.26 (5) 10.16 ± 3.20 (5) 4.76 ± 1.10 (9) 36.43 ± 5.66 (6)***
3233B. Santamaria et al. / Biochimica et Biophysica Acta 1853 (2015) 3224–3234resistance in podocytes through up-regulation of PTEN. Importantly,
suppressing PTEN rescues insulin sensitivity in podocytes and restores
their functions.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.09.020.
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